To investigate the role of folic acid in the management of ribavirin induced haemolytic anaemia in patients on combination treatment for chronic Hepatitis C virus infection

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN07377784

Enrollment

Registered

2004-09-30

Start date

2003-09-01

Completion date

Unknown

Last updated

2016-10-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infections and Infestations: Hepatitis C Infections and Infestations

Interventions

Randomised controlled trial 1. Folic Acid 2. Placebo

Eligibility

Inclusion criteria

Inclusion criteria: 60 patients with chronic hepatitis C virus infection on combination therapy (30 will get folic acid and 30 placebo)

Exclusion criteria

Exclusion criteria: Does not match inclusion criteria

Design outcomes

Primary

Measure	Time frame
Rate of haemoglobin drop and rise and number of patients who have to have Ribavirin dose reduced due to anaemia	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026